- Research article
- Open Access
Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study
BMC Health Services Research volume 21, Article number: 320 (2021)
Subcutaneous (SC) versus intravenous (IV) administration is advantageous in terms of patient convenience and hospital efficiency. This study aimed to compare the effect of optimizing the processes involved in SC versus IV administration of rituximab and trastuzumab on hospital capacity and service quality.
This cross-sectional resource utilization study interviewed oncologists, hematologists, nurses, and pharmacists from 10 hospitals in Spain to estimate changes in processes associated with conversion from IV to SC rituximab and trastuzumab, based on clinical experience and healthcare use from administrative databases.
Efficient use of SC formulations increased the monthly capacity for parenteral administration by 3.35% (potentially increasable by 5.75% with maximum possible conversion according to the product label). The weekly capacity for hospital pharmacy treatment preparation increased by 7.13% due to conversion to SC formulation and by 9.33% due to transferring SC preparation to the cancer treatment unit (potentially increasable by 12.16 and 14.10%, respectively). Monthly hospital time decreased by 33% with trastuzumab and 47% with rituximab. In a hypothetical hospital, in which all processes for efficient use of SC rituximab and/or trastuzumab were implemented and all eligible patients received SC formulations, the estimated monthly capacity for preparation and administration increased by 23.1% and estimated hospital times were reduced by 60–66%.
Conversion of trastuzumab and rituximab to SC administration could improve the efficiency of hospitals and optimize internal resource management processes, potentially increasing care capacity and improving the quality of care by reducing time spent by patients at hospitals.
Rituximab (MabThera®; Roche) and trastuzumab (Herceptin®; Roche) were the first monoclonal antibodies (mAbs) approved for cancer treatment by the European Medicines Agency (EMA) in 1998 and 2000, respectively [1, 2]. The introduction of these drugs revolutionized the treatment of hematological and solid malignancies, with both becoming the standard of care for their respective indications. Both mAbs were first developed as intravenous (IV) formulations with weight-dependent dosing. Subsequently, Roche developed subcutaneous (SC) formulations of rituximab and trastuzumab by concentrating the IV formulations and adding recombinant human hyaluronidase, which enabled SC delivery of effective drug volumes . Preclinical and clinical trials demonstrated that the IV and SC formulations of both drugs had similar pharmacokinetic, efficacy, and safety profiles [4,5,6,7,8,9]. As a result, the EMA approved SC trastuzumab for early and metastatic breast cancer in 2013, and SC rituximab for non-Hodgkin’s lymphoma in 2014 [10, 11]. The Spanish Agency for Medicines and Health Products approved SC trastuzumab in 2014 and SC rituximab in 2015.
Unlike their IV formulations, SC rituximab and SC trastuzumab offer a shorter drug administration time (< 5 min) and contain fixed doses administered by a single-use injection device; therefore, the dosages are independent of the patient’s body weight [10, 11]. In addition, there is no need for a loading dose with SC trastuzumab . Because of the need for weight-based dosing, IV doses of rituximab and trastuzumab must be prepared in hospital pharmacies using a vertical laminar flow hood in order to ensure the quality of the active substance, which is not necessary with the SC formulations. As a result, both drug preparation and administration times are shorter with the SC than with the IV formulations, which has led to relevant economic benefits [12,13,14,15,16,17], as well as a positive impact on patients’ drug preferences [18,19,20,21] and quality of life [17, 22]. Altogether, these benefits may also improve the efficiency of onco-hematology hospitals by optimizing healthcare resource utilization and reducing the patients’ duration of hospital stay.
The primary objective of the present study was to quantify the effects of SC versus IV formulations of rituximab and trastuzumab on the efficiency of Spanish hospitals in terms of healthcare capacity and quality of the services. As a secondary objective, we estimated the impact of SC versus IV treatment on the efficiency of a theoretical hospital that optimizes all of the processes identified in the first part of the study.
This was a two-phase, observational, cross-sectional study, in which participants (hematologists, oncologists, hematology nurses, oncology nurses, and hospital pharmacists) were interviewed to collate resource use information.
Five different questionnaires were developed and validated for use during the face-to-face interviews, and were tailored to each type of healthcare professional (HCP) that were interviewed. The questionnaires were used to gather information from the participant HCPs on resource use based on their recent clinical experience with the management of patients receiving rituximab or trastuzumab. The first questionnaire, for pharmacists, focused on the treatment preparation process; the next two were for oncologists and hematologists (specific for trastuzumab and rituximab, respectively), which focused on the prescription process, disease management including visits and monitoring; and the last two were for nurses (one specific for trastuzumab and the other for rituximab), which focused on the administration process including hospital opening hours, number of daily administrations, number of infusion chairs and average occupancy time. See Additional file 1 for the detailed questionnaires.
In the first phase, fieldwork research was conducted by interviewing HCPs (hematologists, oncologists, nurses, and hospital pharmacists) from reference hospitals in different regions of Spain (Fig. 1). The aim of this fieldwork research was to: (1) identify all of the processes optimized by the use of the SC formulation in these Spanish hospitals; (2) determine performance indicators that would serve as measures to analyze changes in processes, times, volumes, and drug administration due to the SC conversion of both rituximab and trastuzumab; and (3) quantify the improvement in efficiency and healthcare quality as a result of the switch from IV to SC formulations.
From the data collected in the fieldwork, seven parameters were identified that could be used to measure the impact of the identified optimized processes with SC formulations on capacity (four parameters) and quality (three parameters). Capacity parameters were defined as the estimated time spent preparing and administering treatments (Table 1), and quality parameters were defined as the duration of hospital stay, impact on patients’ and/or caregivers’ labor productivity, and the need for a venous access device with a reservoir (Table 1).
In the second phase of the study, the change in healthcare capacity and quality were estimated for a hypothetical hospital, in which all the identified processes would be implemented and the maximum number of patients would be administered SC formulations of rituximab and trastuzumab, according to their respective approved summary of product characteristics (SmPC). Based on the potential total number of patients eligible to receive either IV rituximab or trastuzumab per indication and selecting only SC-approved indications, it was estimated that 45% of all rituximab doses and 91% of all trastuzumab doses could be administered using the SC formulations.
The impact of SC versus IV treatment on the seven defined parameters were described as number of units (N), percentages (%) or presented in other units of measure (i.e., hours or euros [€]) as required in each case. Aggregated results were calculated using the mean value of the percentage variation of all the hospitals considered for each parameter.
The study included 10 reference hospitals from across Spain (Fig. 1). Seven hospitals provided data on the use of trastuzumab and rituximab, two provided data only on the use of trastuzumab, and one provided data only on the use of rituximab. At centers administering rituximab (n = 8), the proportion of patients who received SC rather than IV infusions of rituximab as part of a chemotherapy regimen ranged from 0.0 to 53.3%, and SC rituximab as part of maintenance therapy ranged from 36.2 to 100.0%. A similar trend was seen with use of SC trastuzumab at the nine centers where this treatment was studied. When used in combination with chemotherapy, between 0.0 and 91.7% of the trastuzumab doses were administered by SC infusion, and when used as part of maintenance therapy, between 39.8 and 100.0% of the trastuzumab doses were given by SC infusion. Overall, hospitals had converted between 31.3 and 96.0% of trastuzumab doses and between 36.6 and 68.2% of rituximab doses from IV to SC administration.
Identified processes for efficient use of SC administration
During the interviews, five processes were identified that were already implemented by the hospitals to optimize the efficient administration of SC rituximab and SC trastuzumab. These processes were: (1) preferential use of SC over IV treatments, whenever possible, with specific separate protocols in place for SC and IV administration (e.g., a dedicated chair for SC administration within the cancer treatment unit); (2) required oral premedication prior to the use of rituximab administered to the patient while they were in the waiting room; (3) patients receiving SC treatment at their nearest regional hospital (instead of receiving it in the reference hospital), whenever possible; (4) preparation of SC treatments outside the vertical laminar flow hood (at the hospital pharmacy, the cancer treatment unit or the regional hospital pharmacy); and (5) avoidance of venous access devices in patients receiving trastuzumab, whenever possible. Nevertheless, it was assumed that not all of the participating centers were able to implement all of these processes due to their internal therapeutic protocols and established management procedures.
Eight of the 10 hospitals (80.0%) had a dedicated chair within the cancer treatment unit for SC administration only. At the eight centers where rituximab was administered, seven hospitals (87.5%) started the administration of necessary premedication to patients while they were in the waiting room prior to the use of SC rituximab. Two hospitals treated patients from outside their reference areas, of which one of these hospitals (50.0%) had implemented a protocol for preparing and administering SC treatments to patients at their local regional hospital instead of at the reference hospital. Two of the 10 hospitals (20.0%) had established protocols for preparing SC treatments outside the vertical laminar flow hood (at the hospital pharmacy or the cancer treatment unit). Seven of the nine hospitals that administered trastuzumab (77.8%) were able to avoid using venous access devices in patients by converting from IV to SC formulation.
Impact of SC formulations on hospital capacity
Increase in treatment administration at the cancer treatment unit due to IV to SC conversion
Across the 10 hospitals, the conversion of rituximab and trastuzumab treatment from IV to SC administration increased the total number of treatments that were able to be administered monthly by 3.35%, due to reductions in time when the administration chair was occupied.
Increase in treatment administration due to rituximab premedication being administered in waiting room
In addition to the increased treatment capacity due to conversion of rituximab and trastuzumab from IV to SC, the total number of treatments that could be administered in the cancer treatment unit increased by 0.31% when premedication of rituximab was administered in the waiting room, which was possible with SC rituximab administration.
Increase in treatments that can be prepared and administered at the reference hospital because patients receiving SC can be treated at hospitals closer to their homes
Due to the availability of SC administration, two of 10 centers admitted patients from outside of their reference area, and only one offered the possibility of SC trastuzumab administration at other regional hospitals. The transfer of SC administration for some patients to regional hospitals increased the monthly capacity for treatment administration at the reference hospital by 0.17%. Moreover, at the reference hospital, the weekly capacity of the hospital pharmacy to prepare treatments under the laminar flow hood increased by 0.53% as a result of patient referral to the nearby regional hospitals. Furthermore, patients required notably less travelling time to get the regional hospital.
Increase in treatments that can be prepared in the vertical laminar flow hood at the hospital pharmacy
Overall, based on the measured use of SC rituximab and/or trastuzumab at these centers and the total time savings involved in dose preparation, the weekly capacity to prepare treatment under the laminar flow hood increased by 7.13% as a result of the conversion from IV to SC formulation. On the other hand, transferring the preparation of SC formulations to the cancer treatment unit, rather than at the hospital pharmacy, allowed for a 9.33% increase in the weekly capacity to prepare other treatments under the laminar flow hood of the hospital pharmacy.
Impact on quality of care
Reduction in time spent in hospital
The impact of IV to SC conversion on the time spent in hospital differs depending on whether it is administered in combination with chemotherapy or as monotherapy (Table 2). Compared with IV administration, SC administration of trastuzumab was associated with a 32.89% total reduction in the average monthly hospitalization time (Fig. 2a), while SC rituximab was associated with a 46.96% total reduction (Fig. 2b). The most significant change was seen in the time spent by patients in the administration chair; waiting time at the cancer treatment unit and medical consultation times were also reduced, but to a smaller extent.
Improvement in caregiver’s and/or patient’s work productivity
The reduction in total hospitalization time for patients receiving trastuzumab and rituximab, both in combination with chemotherapy and as maintenance therapy, led to a 21.2% average increase in caregiver or patient work productivity (Table 3). The largest improvement in work productivity was seen with conversion of trastuzumab IV to SC formulation for patients receiving maintenance therapy (34.7% increase). Work productivity for patients receiving trastuzumab in combination with chemotherapy or either type of rituximab therapy increased by 9.9 to 19.2%.
Reduction in the use rate and time of venous access devices with reservoirs
In the case of trastuzumab, conversion to SC treatment also reduced the need for venous access devices with a reservoir (port-a-cath) in patients with early breast cancer (those with metastatic breast cancer have venous catheters inserted due to the need for multiple treatment lines, with the port-a-cath device being the preferred option at most of the assessed hospitals). For these early breast cancer patients, conversion from IV to SC trastuzumab administration allowed for the use of a peripherally inserted central catheter (PICC) instead of a port-a-cath device during the concomitant administration with chemotherapy at these hospitals, with removal of the PICC during maintenance therapy. Therefore, the rate of venous access device use during maintenance therapy was reduced by 81% and the time of use was reduced by 78%.
Impact on capacity and quality of care of a hypothetical hospital that optimizes all identified processes with SC formulation
Table 4 shows the potential results that could be obtained from a hypothetical hospital if all of the identified improvements in efficiencies were implemented and the maximum possible conversion of IV rituximab (45%) and IV trastuzumab (91%) to SC formulations was adopted, according to their respective SmPC.
With maximum possible conversion of IV rituximab and trastuzumab to SC administration, the monthly capacity for treatment administration was estimated to increase by 5.75% as a result of the conversion from IV to SC formulations and the establishment of differential SC administration protocols. Administration of SC rituximab premedication in the waiting room was estimated to increase monthly administration capacity by 0.40%, and the transferal of SC trastuzumab administration to regional hospitals was estimated to increase monthly administration capacity by 1.50%.
With the maximum conversion of IV trastuzumab to SC administration, weekly capacity for preparation of additional treatments by the hospital pharmacy was estimated to increase by 12.16% as a result of the conversion of IV to SC administration, and by 14.10% as a result of transferring SC preparation to the cancer treatment unit. The transferal of SC trastuzumab administration to regional hospitals was estimated to increase the weekly capacity of the hospital pharmacy to prepare treatments under the laminar flow hood by 1.30%, according to trastuzumab SmPC indications.
According to these estimates, in a hypothetical hospital, the implementation of all processes to maximize the use of SC treatments in as many eligible patients as possible may increase the monthly capacity of the treating hospital by up to 23.1%. Mean hospital times per patient were estimated to decrease by 60% due to conversion from IV to SC trastuzumab (Fig. 2c) and by 66% due to conversion from IV to SC rituximab (Fig. 2d). This resulted in an estimated 32.5% increase in annual labor productivity for caregivers and active patients.
Previous studies have indicated that the use of SC versus IV formulations can reduce the time and costs involved in treatment . However, to the best of our knowledge, the H-Excelencia study is the first to estimate the impact of conversion from IV to SC administration on hospital capacity and healthcare quality in the onco-hematology setting in Spain. This study showed that conversion from IV to SC administration of trastuzumab and rituximab improved onco-hematology hospital efficiency by increasing the capacity for treatment preparation and administration. Likewise, conversion to SC treatment reduced the time spent by patients at the hospital for treatment (with a positive impact on the patients’ and caregivers’ labor productivity), as well as reducing the utilization of IV access devices with a reservoir. The present study also showed that further improvements in hospital capacity and patient convenience were possible if the hospital implemented more efficient processes for drug preparation and administration (e.g., use of a dedicated chair for SC administration, administration of SC treatment at the nearest regional hospital whenever possible, and preparation of SC formulations outside of the laminar flood hood), together with maximizing the use of SC formulations of rituximab and trastuzumab whenever possible, according to their respective SmPC.
Previous studies have indicated that the use of SC rather than IV formulations of rituximab and trastuzumab is associated with reduced healthcare utilization and costs [12,13,14,15,16,17, 24,25,26]. In time and motion studies conducted alongside randomized clinical trials, rituximab SC and trastuzumab SC were associated with reductions in active HCP time (spent on both preparation and administration of rituximab SC and trastuzumab SC), as well as reduced time in the administration chair at the cancer treatment unit [13, 16]. With regard to reductions in healthcare utilization, the findings from a Spanish analysis of PrefHer study data were similar to those obtained in the current study: conversion from IV to SC trastuzumab administration led to a 50% reduction in active HCP time, and an 80% reduction in patient chair time .
Real-world studies have also consistently reported reductions in resource utilization and costs associated with conversion from IV to SC administration of rituximab and trastuzumab [12, 14, 15, 17, 24, 25]. While these studies had similar conclusions, the magnitude of the estimated savings differed between studies. Unlike our study, most of these aforementioned studies were based on the direct observation of both patients and HCPs rather than direct interviews with HCPs as in the current study, which might explain some of these differences. However, a recently published French observational study reported that conversion from IV to SC administration of trastuzumab and rituximab resulted in a 2.7% increase in the total number of chemotherapy sessions in the unit (with the potential to reach a 4.2% increase) , which is consistent with the 3.35% increase in the number of administered treatments seen in our study.
As described, most studies have used an observational methodology, but very few have been based on direct interviews with HCPs like the current study [24, 25]. Despite these studies being performed in different countries (Denmark  and Malaysia ), the HCP estimates of cost savings achieved with conversion from IV to SC trastuzumab formulation are quite consistent across these different sites.
The present study has several strengths. First, we used local data with direct input from HCPs involved in the treatment of patients (oncology, hematology, pharmacy, and nursing) to accurately reflect routine treatment practices, and the collected results are based on the aggregated data of the whole population of patients treated at the study sites. In addition, the identified efficiency indicators (Table 1) were developed after methodical and detailed fieldwork research consisting of face-to-face questionnaire-based interviews with HCPs from the same 10 hospitals where the study data were eventually collected. Finally, our analysis has estimated the maximum possible savings that can hypothetically be achieved by implementing processes to improve the efficiency of rituximab and trastuzumab administration and by using SC formulations as much as possible, based on the products’ approved indications. However, this study presents some limitations. First, the estimations of treatment and preparation time data by HCPs were obtained directly from the interviews, without being verified through direct observation, and could therefore be a source of recall bias. Nevertheless, since the estimated reduction in administration times observed in our study are consistent with those reported in similar studies in other countries [24, 25], we can conclude this limitation is unlikely to have significantly influenced our study results. Our study included 10 hospitals from evenly distributed geographic sites across Spain, and although they were of different sizes, and included both public and private institutions, our results would likely have varied if hospitals different to these had been included in the study. Thus our results may not be generalizable to all hospitals. While our study identified processes within participating hospitals that can be targeted to improve resource use, it is possible that other hospitals optimize different operational processes to those in our study. If these had also been included in our study, we might have observed an increased impact both in the capacity and quality of care compared with what was estimated in our study. Additional similar studies should be performed in the future to identify different hospital processes optimized across hospitals in Spain.
This study has revealed new possibilities for improving resources and patient management in onco-hematology services. The use of SC rituximab and trastuzumab formulations improved the efficiency of the Spanish hospitals participating in the present study, increasing the monthly treatment administration and preparation capacity, decreasing administration times, and allowing for the optimization of processes. The quality of healthcare at these hospitals also improved by decreasing the average time of hospitalization and thus increasing the annual work productivity of patients and caregivers. Moreover, implementing similar processes and maximizing the use of SC formulations whenever possible could further enhance healthcare capacity, with an estimated 23.1% increase in the ability to administer other treatments and a > 60% reduction in time spent in hospital.
Availability of data and materials
The datasets used and/or analysed during the current study, data associated and patient survey are available from the corresponding author on reasonable request.
Peripherally inserted central catheter
Summary of product characteristics
European Medicines Agency. MabThera (rituximab) [summary of product characteristics]. 2008. https://www.ema.europa.eu/documents/product-information/mabthera-epar-product-information_en.pdf. Accessed 4 Dec 2018.
European Medicines Agency. Herceptin (trastuzumab) [summary of product characteristics]. 2010. https://www.ema.europa.eu/documents/product-information/herceptin-epar-product-information_en.pdf. Accessed 4 Dec 2018.
Shpilberg O, Jackisch C. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br J Cancer. 2013;109(6):1556–61. https://doi.org/10.1038/bjc.2013.371.
Davies A, Berge C, Boehnke A, Dadabhoy A, Lugtenburg P, Rule S, Rummel M, McIntyre C, Smith R, Badoux X. Subcutaneous rituximab for the treatment of B-cell hematologic malignancies: a review of the scientific rationale and clinical development. Adv Ther. 2017;34(10):2210–31. https://doi.org/10.1007/s12325-017-0610-z.
Gligorov J, Curigliano G, Muller V, Knoop A, Jenkins V, Verma S, et al. Switching between intravenous and subcutaneous trastuzumab: safety results from the PrefHer trial. Breast. 2017;34:89–95. https://doi.org/10.1016/j.breast.2017.05.004.
Ismael G, Hegg R, Muehlbauer S, Heinzmann D, Lum B, Kim SB, Pienkowski T, Lichinitser M, Semiglazov V, Melichar B, Jackisch C. Subcutaneous versus intravenous administration of (neo) adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012;13(9):869–78. https://doi.org/10.1016/S1470-2045(12)70329-7.
Lugtenburg P, Avivi I, Berenschot H, Ilhan O, Marolleau JP, Nagler A, Rueda A, Tani M, Turgut M, Osborne S, Smith R, Pfreundschuh M. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017;102(11):1913–22. https://doi.org/10.3324/haematol.2017.173583.
Salar A, Avivi I, Bittner B, Bouabdallah R, Brewster M, Catalani O, Follows G, Haynes A, Hourcade-Potelleret F, Janikova A, Larouche JF, McIntyre C, Pedersen M, Pereira J, Sayyed P, Shpilberg O, Tumyan G. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase IB study. J Clin Oncol. 2014;32(17):1782–91. https://doi.org/10.1200/JCO.2013.52.2631.
Solal-Celigny P. Rituximab by subcutaneous route. Expert Rev Hematol. 2015;8(2):147–53. https://doi.org/10.1586/17474086.2015.1024651.
European Medicines Agency. MabThera (rituximab): assessment report for variation in summary of product characteristics (EMA/276108/2016). 2016. https://www.ema.europa.eu/documents/variation-report/mabthera-h-c-165-x-101-g-epar-assessment-report-variation_en.pdf. Accessed 4 Dec 2018.
European Medicines Agency. Herceptin (trastuzumab): assessment report for variation in summary of product characteristics (EMA/CHMP/751770/2012/corr1). 2013. https://www.ema.europa.eu/documents/variation-report/herceptin-h-c-278-x-0060-epar-assessment-report-extension_en.pdf. Accessed 4 Dec 2018.
Ponzetti C, Canciani M, Farina M, Era S, Walzer S. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey. Clin Outcomes Res. 2016;8:227–33. https://doi.org/10.2147/CEOR.S97319.
Lopez-Vivanco G, Salvador J, Diez R, Lopez D, De Salas-Cansado M, Navarro B, et al. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain. Clin Transl Oncol. 2017;19(12):1454–61. https://doi.org/10.1007/s12094-017-1684-4.
Franken MG, Kanters TA, Coenen JL, de Jong P, Koene HR, Lugtenburg PJ, Jager A, Uyl-de Groot CA. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands. Anti-Cancer Drugs. 2018;29(8):791–801. https://doi.org/10.1097/CAD.0000000000000648.
Favier M, Le Goc-Sager F, Vincent-Cantini I, Launay V, Giroux EA, Lievremont K, et al. Medico-economic benefits of subcutaneous formulations of trastuzumab and rituximab in day hospitalisation (SCuBA study) [in French]. Bull Cancer. 2018;105(10):862–72. https://doi.org/10.1016/j.bulcan.2018.07.014.
De Cock E, Kritikou P, Sandoval M, Tao S, Wiesner C, Carella AM, et al. Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS One. 2016;11(6):e0157957. https://doi.org/10.1371/journal.pone.0157957.
Cichetti A, Coretti S, Mascia DM, Refolo P, Rolli FR, Rumi F. Assessing social and economic impact of subcutaneous mAbs in oncology. Global Region Health Tech Assess. 2018. https://doi.org/10.1177/2F2284240318757871.
Pivot X, Spano JP, Espie M, Cottu P, Jouannaud C, Pottier V, Moreau L, Extra JM, Lortholary A, Rivera P, Spaeth D, Attar-Rabia H, Benkanoun C, Dima-Martinez L, Esposito N, Gligorov J. Patients’ preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: results of the randomised MetaspHer study. Eur J Cancer. 2017;82:230–6. https://doi.org/10.1016/j.ejca.2017.05.009.
Pivot X, Gligorov J, Muller V, Curigliano G, Knoop A, Verma S, et al. Patients’ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol. 2014;25(10):1979–87. https://doi.org/10.1093/annonc/mdu364.
Pivot X, Gligorov J, Muller V, Barrett-Lee P, Verma S, Knoop A, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. Lancet Oncol. 2013;14(10):962–70. https://doi.org/10.1016/S1470-2045(13)70383-8.
Rummel M, Kim TM, Aversa F, Brugger W, Capochiani E, Plenteda C, Re F, Trask P, Osborne S, Smith R, Grigg A. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab). Ann Oncol. 2017;28(4):836–42. https://doi.org/10.1093/annonc/mdw685.
Syrios J, Pappa E, Volakakis N, Grivas A, Alafis J, Manioudaki S, et al. Real-world data on health-related quality of life assessment in patients with breast cancer receiving subcutaneous trastuzumab. Breast Cancer (Auckl). 2018. https://doi.org/10.1177/2F1178223418758031.
Instituto Nactional de Estadistica. Labour market. 2018. http://www.ine.es/dyngs/INEbase/es/categoria.htm?c=Estadistica_P&cid=1254735976596. Accessed 4 Dec 2018.
Olsen J, Jensen KF, Olesen DS, Knoop A. Costs of subcutaneous and intravenous administration of trastuzumab for patients with HER2-positive breast cancer. J Comp Eff Res. 2018;7(5):411–9. https://doi.org/10.2217/cer-2017-0048.
Lee WC, Haron MR, Yu KL, Chong FLT, Goh A, Azmi S. Economic analysis of intravenous vs. subcutaneously administered trastuzumab for the treatment of HER2+ early breast cancer in Malaysia. Adv Breast Cancer Res. 2016;5(01):1–13. https://doi.org/10.4236/abcr.2016.51001.
Rule S, Collins GP, Samanta K. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ. 2014;17(7):459–68. https://doi.org/10.3111/13696998.2014.914033.
The authors would like to thank the following people for their contributions to the interviews as part of the expert panel: Antonio Antón, Belén Fernández, Teresa Galego and Araceli Rubio from Hospital Universitario Miguel Servet; Rosa Blat, David Conde and Ignacio Tusquets from Hospital del Mar; Loli Fernández, Belén Padrón, Jose Luis Sastre and Luisa Vazquez from Complejo Hospitalario Universitario de Ourense; Mónica Carbajales, Roberto Fernández, Esther González and Maite González from Hospital Universitario de Cabueñes; Francisco Ayala and Concepción Pina from Hospital Universitario Morales Meseguer; Yolanda Bouzada and Maria Teresa Garrido from Hospital Juan Ramón Jimenez; Almudena de la Aldea, Fernando Moreno, Cristina Pérez and Jesús Valles from Hospital Clínico San Carlos; Rafael Flores, David González and Juan Guerra from Hospital Universitario Fuenlabrada; Severina Dominguez, Juan José García Alba and Carlos Peña from Hospital Universitario Txagorritxu; and Nieves Gil Gómez and Nerea Moyano from Hospital Universitario Quironsalud Madrid. The authors also thank Elvira Estella and Isabel Arroyo from Roche Farma for their active participation in the design and development of the study and manuscript edition and review; Verónica Río, Raquel Redondo and Luis Blanco from Roche Farma for their participation in the design and development of the study; Maria Gortázar and Gonzalo Casino from Deloitte Consulting for the execution of the study; and Catherine Rees and Tracy Harrison, both of Springer Healthcare Communications, who provided editing assistance and pre- and post-submission, respectively. This editorial assistance was funded by Roche Farma.
This study was funded by Roche Pharma. This sponsor had a partial role in the study design, and in the collection, analysis, and interpretation of data.
Ethics approval and consent to participate
This study was conducted in accordance with the Declaration of Helsinki. This study did not require approval by any ethics committee as according to the Spanish law (“Ley 14/2007, de 3 de julio, de Investigación biomédica”).
According to the Spanish law (“Ley 41/2002, de 14 de noviembre, básica reguladora de la autonomía del paciente y de derechos y obligaciones en materia de información y documentación clínica el consentimiento informado”), the informed consent has to be signed only when the activity of the study can affect patient’s health status. Since our study is an observational research, conducted through interviews with health care professionals, it was not necessary for patients to sign an informed consent in this study.
Consent for publication
MRA-S reports speakers’ fees from Roche, Shire, Grifols, Janssen, GSK, Merck, Abbvie, Leo-Pharma and Vertex, and non-financial support from Roche and Janssen. JMGdeC reports speakers’ fees from MSD, Roche, Alexion and Novartis, and travel expenses from MSD. JAL has received speakers’ fees from ROCHE. CMC reports speakers’ fees and travel expenses from Roche. AS has received honoraria and speakers’ fees from Roche, Jannsen and Celgene and travel expenses from Roche and Celgene. All other authors declare that they have no competing interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Additional file 1.
Discussion guides during fieldwork research. Additional file 1 describes how field research for this study was conducted. Specifically, it outlines the objectives of the study and the questions that each group of participants was asked.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Abad-Sazatornil, M.R., Arenaza, A., Bayo, J. et al. Impact of the subcutaneous formulations of trastuzumab and rituximab on efficiency and resource optimization in Spanish hospitals: H-Excelencia study. BMC Health Serv Res 21, 320 (2021). https://doi.org/10.1186/s12913-021-06277-8
- Efficiency indicators
- Healthcare capacity
- Healthcare quality
- Resource optimization